Phase 3 study of UX007 in patients with Long-Chain Fatty Acid Oxidation Disorder

Trial Profile

Phase 3 study of UX007 in patients with Long-Chain Fatty Acid Oxidation Disorder

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications Lipid metabolism disorders
  • Focus Therapeutic Use
  • Sponsors Ultragenyx Pharmaceutical
  • Most Recent Events

    • 02 Nov 2017 According to an Ultragenyx media release, the company continue to plan for discussions with regulators regarding the study by the end of 2017.
    • 27 Jul 2017 According to Ultragenyx media release, the company continue to plans for discussion with the regulatory authorities.
    • 15 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top